Technical Analysis for ALLR - Allarity Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.67 | -1.07% | -0.01 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | -1.07% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | -1.07% |
Alert | Time |
---|---|
Possible NR7 | about 5 hours ago |
Possible Inside Day | about 5 hours ago |
Up 5% | about 7 hours ago |
Up 3% | about 7 hours ago |
Up 2% | about 8 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/15/2023
Allarity Therapeutics, Inc. Description
Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Health Sciences Drugs Treatment Of Cancer Enzymes Protein Kinase Inhibitor Tyrosine Kinase Doxorubicin Liposome
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 283.2 |
52 Week Low | 0.643 |
Average Volume | 4,030,824 |
200-Day Moving Average | 12.79 |
50-Day Moving Average | 3.61 |
20-Day Moving Average | 1.08 |
10-Day Moving Average | 0.79 |
Average True Range | 0.37 |
RSI (14) | 12.28 |
ADX | 32.35 |
+DI | 33.27 |
-DI | 23.30 |
Chandelier Exit (Long, 3 ATRs) | 2.36 |
Chandelier Exit (Short, 3 ATRs) | 1.74 |
Upper Bollinger Bands | 1.69 |
Lower Bollinger Band | 0.47 |
Percent B (%b) | 0.16 |
BandWidth | 112.52 |
MACD Line | -0.77 |
MACD Signal Line | -0.92 |
MACD Histogram | 0.1483 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.76 | ||||
Resistance 3 (R3) | 0.76 | 0.74 | 0.74 | ||
Resistance 2 (R2) | 0.74 | 0.72 | 0.74 | 0.74 | |
Resistance 1 (R1) | 0.71 | 0.71 | 0.70 | 0.70 | 0.73 |
Pivot Point | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 |
Support 1 (S1) | 0.65 | 0.66 | 0.64 | 0.64 | 0.61 |
Support 2 (S2) | 0.63 | 0.65 | 0.63 | 0.61 | |
Support 3 (S3) | 0.59 | 0.63 | 0.60 | ||
Support 4 (S4) | 0.59 |